All studies
RecruitingOBSERVATIONAL

GMMG Multiple Myeloma Registry

This study, called the GMMG Multiple Myeloma Registry, is designed to keep track of the long-term health of people in Germany with multiple myeloma. These individuals have previously participated in treatment studies run by a group called the German-Speaking Myeloma Multicenter Group (GMMG). The main goal is to collect information on how patients do over many years, looking at things like how long they live, how long they stay free from their cancer getting worse, and how their treatment plans change over time. By combining this new information with data from previous studies, researchers hope to get a clearer picture of the best ways to treat multiple myeloma and improve patients' lives. This is an 'observational' study, meaning patients receive their usual care, and researchers simply gather information without giving new treatments as part of this specific registry.

At a glance

Status
Recruiting
Sponsor
Prof. Dr. Hartmut Goldschmidt
Enrolment target
999
Start
08 Dec 2022
Estimated completion
01 Mar 2027

What is this study about?

This registry is a long-term study that collects important health information from people in Germany who have multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow. The people included in this registry have already taken part in previous treatment studies led by a group called the German-Speaking Myeloma Multicenter Group (GMMG).

The main idea behind this registry is to continue gathering information about these patients over many years, even after their original treatment studies have finished. This helps doctors and researchers understand the long-term effects of different treatments. They want to see how long people live overall, how long they stay well without their cancer getting worse, and what happens to their health over a long period. By combining this new, ongoing information with what they already know from the previous studies, they can learn a great deal about the best ways to manage multiple myeloma.

This kind of study is really important because it helps improve future care for others with multiple myeloma. It provides valuable insights into how treatments work in the real world and over time, allowing doctors to make more informed decisions and develop better treatment strategies. It started in late 2022 and involves many cancer centers across Germany.

Key takeaways

  • This is a registry for people with multiple myeloma who were in past GMMG studies.
  • It collects long-term health information to understand treatment effects over many years.
  • No new treatments are given; you'll receive your usual care.
  • Information is collected every 6-12 months.
  • Your participation helps improve future care for multiple myeloma patients.
  • You can withdraw from the registry at any time.

Who may be eligible?

To be part of this registry, you must have previously participated in a treatment study run by the German-Speaking Myeloma Multicenter Group (GMMG). This means you would have already been treated for multiple myeloma as part of one of their specific research trials.

People who had a condition called organ amyloidosis at the time they were diagnosed with multiple myeloma would not be able to join this registry. Organ amyloidosis is when abnormal proteins build up in organs and can cause health problems.

This registry is open to adults aged 18 and older, and it includes both men and women.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. Have I been diagnosed with multiple myeloma?
  2. Did I previously take part in a treatment study from the GMMG group?
  3. Am I aged 18 or older?
  4. Did I NOT have organ amyloidosis when I was first diagnosed with multiple myeloma?
Answer every question to see your result.

What does participation involve?

If you are eligible and agree to take part, your contribution to this registry will mainly involve allowing researchers to continue gathering information about your health. You will continue to receive your standard medical care from your own doctors, as you normally would. This study does not involve new treatments or medical procedures.

Researchers will collect information every six months until your cancer progresses (gets worse). After that, they will collect information once a year. This data includes details about your treatment, your current health, and how you are doing. The information collected will be kept private and stored in a secure electronic system. You can choose to stop participating at any time.

Potential risks and benefits

There are no direct medical risks or benefits to participating in this registry, as it simply involves collecting your existing health information. You will continue to receive your usual medical care from your own doctors. The main benefit is that your information will help doctors and researchers better understand multiple myeloma and improve future treatments for others. Your health information will be kept confidential and anonymised as much as possible to protect your privacy. You are always free to withdraw your consent and stop participating in the registry at any time without affecting your medical care.

Locations (35)

  • HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie
    Verified postcode
    Berlin, Germany· Recruiting
  • Charité Campus Benjamin Franklin, III. Med. Abt. (Hämatologie/Onkologie)
    Verified postcode
    Berlin, Germany· Recruiting
  • Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin
    Verified postcode
    Bielefeld, Germany· Recruiting
  • Medizinische Universitätsklinik, Knappschaftskrankenhaus
    Verified postcode
    Bochum, Germany· Recruiting
  • Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie
    Verified postcode
    Bonn, Germany· Recruiting
  • Klinikum Chemnitz GmbH, Innere Medizin III
    Verified postcode
    Chemnitz, Germany· Recruiting
  • Universitätsklinikum Köln, Klinik I - Innere Medizin
    Verified postcode
    Cologne, Germany· Recruiting
  • Onkologisches Studienzentrum Darmstadt
    Verified postcode
    Darmstadt, Germany· Recruiting
  • Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie
    Verified postcode
    Darmstadt, Germany· Recruiting
  • Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. Immunologie
    Verified postcode
    Düsseldorf, Germany· Recruiting
  • Universitätsklinik Erlangen
    Verified postcode
    Erlangen, Germany· Recruiting
  • Universitätsklinikum Essen, Klinik für Hämatologie und Stammzelltransplantation
    Verified postcode
    Essen, Germany· Recruiting

Common questions

What is the main goal of this registry?

The main goal is to collect long-term health information from people with multiple myeloma who were in previous GMMG treatment studies, to understand how treatments affect them over time.

Will I receive new treatment as part of this study?

No, this is an observational study. You will continue to receive your standard medical care from your own doctors, and no new treatments are given as part of this registry.

How often will my information be collected?

Your health information will be collected every six months until your cancer progresses, and then once a year after that.

What kind of information will be collected?

Researchers will collect details about your treatments, how your health is doing, and important milestones like how long you stay well or if your condition changes.

Can I stop participating if I change my mind?

Yes, you can choose to stop participating in the registry at any time, and this will not affect the medical care you receive.

How to find out more

Eileen Kurre

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "GMMG Multiple Myeloma Registry…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.